A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning
Xin Su Ning (XSN) is a China patented and certified traditional Chinese herbal medicine used to treat premature ventricular contractions (PVCs) since 2005. XSN is formulated with 11 herbs, designed to treat arrhythmia with phlegm-heat heart-disturbed syndrome (PHHD) according to Chinese medicine the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01138/full |
| _version_ | 1819168814564114432 |
|---|---|
| author | Taiyi Wang Taiyi Wang Hamish Streeter Hamish Streeter Xuan Wang Xuan Wang Ujang Purnama Ming Lyu Carolyn Carr Yu-ling Ma Yu-ling Ma |
| author_facet | Taiyi Wang Taiyi Wang Hamish Streeter Hamish Streeter Xuan Wang Xuan Wang Ujang Purnama Ming Lyu Carolyn Carr Yu-ling Ma Yu-ling Ma |
| author_sort | Taiyi Wang |
| collection | DOAJ |
| description | Xin Su Ning (XSN) is a China patented and certified traditional Chinese herbal medicine used to treat premature ventricular contractions (PVCs) since 2005. XSN is formulated with 11 herbs, designed to treat arrhythmia with phlegm-heat heart-disturbed syndrome (PHHD) according to Chinese medicine theory. The rational compatibility of the 11 herbs decides the therapeutic outcome of XSN. Due to the multicomponent nature of traditional Chinese medicine, it is difficult to use conventional pharmacology to interpret the therapeutic mechanism of XSN in terms of clear-cut drug molecule and target interactions. Network pharmacology/systematic pharmacology usually consider all the components in a formula with the same weight; therefore, the proportion of the weight of the components has been ignored. In the present study, we introduced a novel coefficient to mimic the relative amount of all the components in relation with the weight of the corresponding herb in the formula. The coefficient is also used to weigh the pharmacological effect of XSN on all relative biological pathways. We also used the cellular electrophysiological data generated in our lab, such as the effect of liensinine and isoliquiritigenin on NaV1.5 channels; we therefore set sodium channel as one of the targets of these two components, which would support the clinical efficacy of XSN in treating tachyarrhythmia. Combining the collected data and our discovery, a panoramagram of the pharmacological mechanism of XSN was established. Pathway enrichment and analysis showed that XSN treated PHHD arrhythmia through multiple ion channels regulation, protecting the heart from I/R injury, inhibiting the apoptosis of cardiomyocyte, and improving glucose and lipid metabolism. |
| first_indexed | 2024-12-22T19:09:35Z |
| format | Article |
| id | doaj.art-e07f84dc96f3421882e4a35658d23aa6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T19:09:35Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e07f84dc96f3421882e4a35658d23aa62022-12-21T18:15:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-09-011010.3389/fphar.2019.01138476436A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su NingTaiyi Wang0Taiyi Wang1Hamish Streeter2Hamish Streeter3Xuan Wang4Xuan Wang5Ujang Purnama6Ming Lyu7Carolyn Carr8Yu-ling Ma9Yu-ling Ma10Oxford Chinese Medicine Research Centre, University of Oxford, Oxford, United KingdomDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United KingdomOxford Chinese Medicine Research Centre, University of Oxford, Oxford, United KingdomDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United KingdomOxford Chinese Medicine Research Centre, University of Oxford, Oxford, United KingdomDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United KingdomDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United KingdomInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United KingdomOxford Chinese Medicine Research Centre, University of Oxford, Oxford, United KingdomDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United KingdomXin Su Ning (XSN) is a China patented and certified traditional Chinese herbal medicine used to treat premature ventricular contractions (PVCs) since 2005. XSN is formulated with 11 herbs, designed to treat arrhythmia with phlegm-heat heart-disturbed syndrome (PHHD) according to Chinese medicine theory. The rational compatibility of the 11 herbs decides the therapeutic outcome of XSN. Due to the multicomponent nature of traditional Chinese medicine, it is difficult to use conventional pharmacology to interpret the therapeutic mechanism of XSN in terms of clear-cut drug molecule and target interactions. Network pharmacology/systematic pharmacology usually consider all the components in a formula with the same weight; therefore, the proportion of the weight of the components has been ignored. In the present study, we introduced a novel coefficient to mimic the relative amount of all the components in relation with the weight of the corresponding herb in the formula. The coefficient is also used to weigh the pharmacological effect of XSN on all relative biological pathways. We also used the cellular electrophysiological data generated in our lab, such as the effect of liensinine and isoliquiritigenin on NaV1.5 channels; we therefore set sodium channel as one of the targets of these two components, which would support the clinical efficacy of XSN in treating tachyarrhythmia. Combining the collected data and our discovery, a panoramagram of the pharmacological mechanism of XSN was established. Pathway enrichment and analysis showed that XSN treated PHHD arrhythmia through multiple ion channels regulation, protecting the heart from I/R injury, inhibiting the apoptosis of cardiomyocyte, and improving glucose and lipid metabolism.https://www.frontiersin.org/article/10.3389/fphar.2019.01138/fullXin Su Ningnetwork pharmacologyphlegm-heat heart-disturbanceweight coefficientcardiac arrhythmiaelectrophysiology |
| spellingShingle | Taiyi Wang Taiyi Wang Hamish Streeter Hamish Streeter Xuan Wang Xuan Wang Ujang Purnama Ming Lyu Carolyn Carr Yu-ling Ma Yu-ling Ma A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning Frontiers in Pharmacology Xin Su Ning network pharmacology phlegm-heat heart-disturbance weight coefficient cardiac arrhythmia electrophysiology |
| title | A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning |
| title_full | A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning |
| title_fullStr | A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning |
| title_full_unstemmed | A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning |
| title_short | A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning |
| title_sort | network pharmacology study of the multi targeting profile of an antiarrhythmic chinese medicine xin su ning |
| topic | Xin Su Ning network pharmacology phlegm-heat heart-disturbance weight coefficient cardiac arrhythmia electrophysiology |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.01138/full |
| work_keys_str_mv | AT taiyiwang anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT taiyiwang anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT hamishstreeter anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT hamishstreeter anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT xuanwang anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT xuanwang anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT ujangpurnama anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT minglyu anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT carolyncarr anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT yulingma anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT yulingma anetworkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT taiyiwang networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT taiyiwang networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT hamishstreeter networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT hamishstreeter networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT xuanwang networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT xuanwang networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT ujangpurnama networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT minglyu networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT carolyncarr networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT yulingma networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning AT yulingma networkpharmacologystudyofthemultitargetingprofileofanantiarrhythmicchinesemedicinexinsuning |